352 related articles for article (PubMed ID: 37292205)
21. Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database.
Xia S; Gong H; Wang YK; Liu L; Zhao YC; Guo L; Zhang BK; Sarangdhar M; Noguchi Y; Yan M
Front Pharmacol; 2023; 14():1129730. PubMed ID: 37007042
[No Abstract] [Full Text] [Related]
22. Evaluation of uveitis events in real-world patients receiving immune checkpoint inhibitors based on the FAERS database.
Fan Q; Chen H; Hu Y; Zhao B
Cutan Ocul Toxicol; 2023 Jun; 42(2):68-73. PubMed ID: 37130046
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Cao Y; Lin Z; Zhou X; Guo Z; He J
Front Cardiovasc Med; 2021; 8():735466. PubMed ID: 34646873
[No Abstract] [Full Text] [Related]
24. Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study.
Li N; Feng Y; Chen X; Li Y; Zhang C; Yin Y
Front Pharmacol; 2023; 14():1213608. PubMed ID: 38026965
[No Abstract] [Full Text] [Related]
25. Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems.
Ma R; Wang Q; Meng D; Li K; Zhang Y
BMC Cancer; 2021 Jan; 21(1):38. PubMed ID: 33413213
[TBL] [Abstract][Full Text] [Related]
26. Hepatobiliary calculi associated with ceftriaxone treatment: An analysis of FAERS data from 2004 to 2021.
Liu X; Xu Z; Ma J; Zhang A; Li Z; Qi G; Li Z; Wei F; Zhong L
J Infect Chemother; 2023 Feb; 29(2):136-142. PubMed ID: 36270450
[TBL] [Abstract][Full Text] [Related]
27. Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database.
Li H; Sun X; Sun D; Zhao J; Xu Z; Zhao P; Ma Z; Zhang Y
Int Immunopharmacol; 2021 Sep; 98():107818. PubMed ID: 34130149
[TBL] [Abstract][Full Text] [Related]
28. Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study.
Xia S; Gong H; Zhao Y; Guo L; Wang Y; Zhang B; Sarangdhar M; Noguchi Y; Yan M
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612235
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Wang F; Wu X
J Clin Pharm Ther; 2022 Oct; 47(10):1576-1584. PubMed ID: 35726369
[TBL] [Abstract][Full Text] [Related]
30. A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database.
Kim JE; Park J; Song TJ
Mult Scler; 2022 Nov; 28(13):2112-2123. PubMed ID: 35822296
[TBL] [Abstract][Full Text] [Related]
31. Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database.
Cui C; Deng L; Wang W; Ren X; Wang Y; Cui W
Front Oncol; 2022; 12():941079. PubMed ID: 36059699
[TBL] [Abstract][Full Text] [Related]
32. Updated Insights on Cardiac and Vascular Risks of Proton Pump Inhibitors: A Real-World Pharmacovigilance Study.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Lin Z; Zhou X; Guo Z; Cao Y; He J
Front Cardiovasc Med; 2022; 9():767987. PubMed ID: 35282344
[TBL] [Abstract][Full Text] [Related]
33. Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System database.
Gao S; He Z; Zhu J; Liang D; Zhao W; Yang S; Jiang W; Qiu K; Yu X; Wu J
Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1199-1205. PubMed ID: 35689298
[TBL] [Abstract][Full Text] [Related]
34. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
35. Nephrotoxicity of Immune Checkpoint Inhibitors: A Disproportionality Analysis from 2013 to 2020.
Qu J; Ding Y; Jiang K; Hao J; Li Y; Zhang A; Li Z; Qi G; Xu Z; Liu X; Ma J; Bi K; Li Z
Tohoku J Exp Med; 2021 Aug; 254(4):275-282. PubMed ID: 34433731
[TBL] [Abstract][Full Text] [Related]
36. Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study.
Zhu J; Wu J; Chen P; You K; Su J; Gao Z; Bi Z; Feng M
Int Immunopharmacol; 2022 Dec; 113(Pt A):109350. PubMed ID: 36272360
[TBL] [Abstract][Full Text] [Related]
37. Immune checkpoint inhibitors increase the risk of kidney transplant rejection: a real-world pharmacovigilance study.
Wu J; Huang J; Zhu J; He Z; Chen M; Gao S; Liang D; Yu X; Lu C
Expert Opin Drug Saf; 2023 Mar; 22(3):231-235. PubMed ID: 35929998
[TBL] [Abstract][Full Text] [Related]
38. Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system.
Moore DC; Elmes JB; Arnall JR; Strassels SA; Patel JN
Int Immunopharmacol; 2022 Sep; 110():109015. PubMed ID: 35803131
[TBL] [Abstract][Full Text] [Related]
39. Arrhythmic events associated with immune checkpoint inhibitors therapy: A real-world study based on the Food and Drug Administration Adverse Event Reporting System database.
Liu Y; Chen Y; Zeng Z; Liu A
Cancer Med; 2023 Mar; 12(6):6637-6648. PubMed ID: 36426382
[TBL] [Abstract][Full Text] [Related]
40. Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system.
Li C; Li Z; Sun Q; Xiang Y; Liu A
Expert Opin Drug Saf; 2024 Jun; 23(6):777-784. PubMed ID: 37622438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
